GPX-002
Undisclosed Solid Tumor
ResearchDiscovery/Preclinical
Key Facts
About Genprex
Genprex is focused on developing life-changing gene therapies for cancer patients, leveraging its unique platform to deliver tumor suppressor genes directly to cancer cells. The company's core technology, the ONCOPREX® Nanoparticle Delivery System, is designed to overcome the limitations of viral vectors and enable systemic administration. Its lead program, Reqorsa®, which delivers the TUSC2 gene, is in multiple clinical trials for lung cancer, positioning the company at the forefront of non-viral gene therapy in oncology. Genprex's strategy involves advancing its pipeline through clinical development and seeking strategic partnerships to maximize the potential of its platform.
View full company profile